RESEARCH ARTICLE

Psychometric evaluation of patient assessment of chronic illness care among Korean cancer survivors

Soo Hyun Kim¹, Bo Gyeong Lee²*, Yu Hyeon Choe¹

¹ Department of Nursing, Inha University, Incheon, South Korea, ² College of Nursing, Research Institute of Nursing Science, Daegu Catholic University, Daegu, South Korea

* leebbo03@gmail.com

Abstract

Background
The Patient Assessment of Chronic Illness Care (PACIC) was developed in the United States to assess the implementation of the Chronic Care Model (CCM)-based intervention from the patient’s perspective. Although the psychometric properties of the PACIC have been reported in other chronically ill patients, it has not been reported in cancer survivors. Our aim was to evaluate the acceptability, validity, and reliability of a Korean version of the PACIC among cancer survivors (K-PACIC-CS).

Methods
Among 204 cancer survivors at a university-based hospital in South Korea, we performed psychometric evaluation of the K-PACIC-CS according to acceptability (descriptive statistics, missing values, and floor and ceiling effects), validity (confirmative factor analysis [CFA] and convergent validity), and reliability (internal consistency, i.e., Cronbach’s alpha).

Results
The item response was high (missing rate = 0.5%). The floor effect was 3.9%–43.6% and the ceiling effect was 6.9%–41.2%. The CFA revealed good indices of fit and confirmed the five structures predetermined in the original version of PACIC. The K-PACIC-CS scores had significant positive relationships with cancer survivors’ self-efficacy and health-related quality of life. The total K-PACIC-CS showed excellent internal consistency (Cronbach’s alpha = .94) and those of the subscales were acceptable (Cronbach’s alpha = .76 -.86).

Conclusions
This study suggests that the K-PACIC-CS is a valid and reliable instrument for measuring implementation of CCM-based chronic care from the survivor’s perspective.
Introduction

Owing to advances in early detection of cancer and its treatment, the number of cancer survivors has increased remarkably. There were more than 16.9 million people with history of cancer in United States (US) in 2019, and that number is projected to reach more than 22.1 million by 2030 [1] and more than 1,800,000 in South Korea in 2019 [2]. To date, approximately 50% of patients diagnosed with cancer survive for 10 years or more [1,3], and that is likely to have a substantial impact on the healthcare system.

Several health challenges face survivors, including managing the adverse effects of cancer and its treatment, seeking information and support, identifying signs and symptoms of disease progression, and making appropriate lifestyle changes for prevention of recurrence or a second cancer [4–6]. Thus, cancer is often viewed as a chronic illness, much like hypertension or diabetes. With this paradigm shift in cancer care, survivors and healthcare providers need to consider that now care is long term, extending beyond the acute phase. This kind of long-term planning requires an ongoing collaborative relationship between survivors and healthcare providers instead of an acute, prescriptive relationship [7].

In order to meet the demand for a new model of cancer care, the Chronic Care Model (CCM) has been suggested [7]. The CCM, which was developed in the US [8] to help general practitioners shift patients from acute care to chronic care, is now widely adopted in various settings [7]. It encourages high-quality care with the following six elements: self-management support, delivery system design, decision support, clinical information systems, healthcare organization, and community resources [8,9]. The goal of CCM-based healthcare is to create an informed, activated patient interacting with a prepared, proactive practice team, resulting in productive encounters and improved outcomes [9–12]. In particular, the “self-management support” element of the CCM enhances patients’ confidence (i.e., self-efficacy) and skills, helping them self-manage their illness [13].

The ability to collect valid data is crucial in evaluating the public-health impact of new initiatives [14]. Glasgow and colleagues [15] developed the Patient Assessment of Chronic Illness Care (PACIC) to assess the quality of patient-centered care for chronic illness consistent with the CCM. The PACIC assesses the receipt of CCM-based chronic care, which emphasizes self-management support (e.g., collaborative goal-setting, problem-solving, and follow-up) and planned, proactive, and population-based care [15]. It has been used to evaluate the delivery of CCM-based intervention for a variety of chronic illness conditions, including diabetes, osteoarthritis, asthma, hypertension, and chronic obstructive pulmonary disease [16–21]. Several studies have demonstrated that the PACIC is an acceptable, valid, and reliable instrument [14,15,22–25], and it is associated with measures of self-management behavior [16,20], self-efficacy [24,26], and health-related quality of life (HRQOL) [27,28].

There are several well-developed tools to assess cancer patients’ needs, such as the Cancer Rehabilitation Evaluation System (CARES) [29], the Comprehensive Needs Assessment Tool in cancer (CNAT) [30], the Need Evaluation Questionnaire (NEQ) [31,32], and the Supportive Care Needs Survey (SCNS) [33]. However, these tools have limitations with regards assessment of the quality of chronic-care delivery. The PACIC is the only tool mentioned in the literature that measures patients’ assessment of chronic-illness care received under the CCM. However, a validation study on the PACIC has not yet been conducted among cancer survivors. In Korea, the PACIC was translated and validated in 2015 [34], but only among patients with hypertension or diabetes. Here, we present data on the psychometric properties of the PACIC among cancer survivors. We examine acceptability, construct validity, and reliability, suggesting the instrument as a potential measure of delivery of CCM-based long-term survivorship care in Korea.
Methods

Study design

This study is a secondary analysis using data from a validation study of Cancer Survivors’ Self-Efficacy Scale (CSSES) among 204 patients who had completed their primary cancer treatment [35]. Original data were collected after approval from the Institutional Review Board of Inha University Hospital (No. INHAUH-2017-04-025), and data access and analysis were additionally approved by the same institution for this study (No. INHAUH-2020-05-033).

Participants and procedures

We recruited 204 study participants from a university-based hospital in Korea using the convenience sampling approach. Participants were: 1) at least 18 years old; 2) those diagnosed with any type of cancer and who had completed their primary treatment (surgery, chemotherapy, or radiation); and 3) those able to read and write Korean. Subjects with evidence of metastasis and/or recurrence, or those undergoing cancer treatment were excluded.

Data were collected from June to July 2017 at an outpatient clinic at Inha University Hospital. Two trained researchers selected eligible patients by visiting potential enrollees in the outpatient department and checking their electronic medical records. During visits, the researchers explained the study, invited participation, and asked for consent to participate. After accepted participants voluntarily signed an informed consent form, the researchers distributed the questionnaire, which took about 20 minutes to complete. Detailed information about recruitment and procedures are described elsewhere [35].

Sample-size calculation

Based on factorial validity, we chose a sample-size of 200, which is generally acceptable for a confirmatory factor analysis (CFA) [36]. Thus, we used original data (N = 204) [35].

PACIC and translation process

The original version of PACIC [15] was developed for patients with chronic diseases, that is, hypertension, arthritis, depression, diabetes, asthma, and chronic pain conditions. It demonstrated for a good facial, construct, and concurrent validity [15]. Internal consistency, that is, the Cronbach’s alpha was .93 for the overall PACIC and the item range was .77 to .90 [15]. The PACIC includes 20 items, comprising five subscales: Patient Activation (items 1–3); Delivery System Design/Decision Support (items 4–6); Goal Setting/Tailoring (items 7–11); Problem Solving/Contextual (items 12–15); and Follow-up/Coordination (items 16–20) [15]. It uses a 5-point Likert scale ranging from 1 (“never”) to 5 (“always”), with higher scores indicating better quality of chronic care from the patient’s perspective. Each subscale is scored by averaging items completed within the scale, and the overall PACIC score is the average across all 20 items (Table 2).

In Korea, Kim [34] translated the PACIC into Korean (K-PACIC) using the method recommended by the World Health Organization (WHO) for translation and adaptation of instruments to ensure cross-cultural validity. The process involved a forward–backward translation, discussion by a panel of experts in the field, a back-translation, an original author’s review, and a reconciliation. The K-PACIC was validated with patients with hypertension and diabetes, and it showed good validity and reliability. Internal consistency as represented by Cronbach’s alpha was .93 [34]. We used the K-PACIC in this study with Kim’s permission. After reviewing the K-PACIC items, we revised item 19 (from “Told how my visits with other types of doctors, such as an eye doctor or surgeon, helped my treatment” to “Told how my visits with other
types of doctors, such as a psychiatrist or rehabilitation physician, helped my treatment”), reflecting the oncology care setting.

**Measures**

**Cancer Survivors’ Self-Efficacy Scale.** The 11 items of the Cancer Survivors’ Self-Efficacy Scale (CSSES) were developed by Foster and colleagues in the United Kingdom (UK) to measure self-efficacy for self-management behaviors in cancer survivors [6]. Each item had 10 response categories with scores ranging from 1 (“not at all”) to 10 (“totally confident”)—higher scores indicating higher self-efficacy. The Korean version of the CSSES (CSSES-K) has 10 items and consists of two subscales, including self-efficacy for managing health problems (five items) and self-efficacy for seeking help and support (five items). It has been validated and has shown good reliability [35]. In the present study, the Cronbach’s alpha was .92.

**HRQOL.** The RAND 36-item Short-Form Health Survey (SF-36) is a reliable and validated instrument for measuring HRQOL [37]. It consists of 36 items, eight health concepts (physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions), and a single item (perceived change in health). Total scores range from 0 to 100, with higher scores indicating better quality of life. In this study, SF-36 was translated according to the guidelines provided by RAND [38]. The Cronbach’s alpha was .93.

**Statistical analysis**

We assessed the psychometric properties of the K-PACIC among cancer survivors (K-PACIC-CS) in terms of acceptability, construct validity, and reliability. We examined acceptability through analysis of data quality using descriptive statistics, including mean and standard deviation, percentage of missing values, and percentage of floor and ceiling effects. The floor and ceiling effects refer to the percentage of respondents using the most extreme (upper or lower) response categories. We considered a frequency less than 30% acceptable [39].

We evaluated the construct validity of the K-PACIC-CS by verifying factorial structure using the CFA and testing convergent validity. We performed the CFA to confirm the factor structure proposed by Glasgow and colleagues [15]. In order to evaluate the model fit, we used the following indices: the comparative fit index (CFI); the normed fit index (NFI); the Tucker Lewis index (TLI); and the root-mean-square error of approximation (RMSEA). If the CFI, NFI, and TLI were greater than .9 and the RMSEA was .05–.08, the results were deemed acceptable [40,41].

In order to test convergent validity, we used Pearson correlation coefficients. We hypothesized that there would be significant positive correlations between the K-PACIC-CS score and the scores of CSSES-K and SF-36. Here, cancer survivors’ self-efficacy refers to self-efficacy for self-management behaviors after cancer treatment. According to mapping of the PACIC subscales onto the CCM elements [42], it is conceptually sound to use the PACIC as a measure of self-management support in care quality assessments. Self-efficacy is an important outcome of self-management support intervention [43] and was found to be significantly associated with a patient’s perceived self-management support [24,26]. Thus, we expected that the K-PACIC-CS score would be positively correlated with the CSSES-K score.

In order to evaluate reliability, we assessed internal consistency by calculating Cronbach’s alpha, considering a value greater than .70 acceptable [44]. In addition, we used descriptive statistics to report participant characteristics and conducted an independent t-test and one-way...
ANOVA to examine the difference in the K-PACIC-CS scores by participant characteristics. We performed all analyses using the SPSS 25.0 and the AMOS program (SPSS Inc, Chicago, Illinois).

**Results**

**Participant characteristics and the K-PACIC-CS scores**

Among 997 potentially eligible participants, 475 did not complete their treatment and 318 refused to participate. Eventually, 204 subjects participated in this study. Table 1 shows participant characteristics and the difference in the K-PACIC-CS scores. The mean age of participants was 54.2 (SD = 11.1) years. Majority of our sample was women (87.7%) and most common types of cancer were breast (75.1%) and gastrointestinal (10.5%) cancers. Almost all (96.6%) had undergone surgery, 66.7% had undergone radiation therapy, and 70.1% had undergone chemotherapy.

Men reported significantly higher K-PACIC-CS scores than women ($p = .006$); thyroid cancer survivors had the lowest K-PACIC-CS scores ($p = .021$); participants diagnosed with Stage 3 showed significantly higher K-PACIC-CS scores as compared to those with Stages 0, 1, or 2. Participants whose treatment had been completed less than 12 months ago revealed significantly higher K-PACIC-CS scores than those whose treatment had been completed more than 36 months ago ($p = .002$) (Table 1).

**Acceptability**

Table 2 presents descriptive statistics of the K-PACIC-CS. The missing rate was only 0.5%, and only Item 5 had a missing value.

**Validity**

**Factorial validity: CFA.** We performed the CFA according to the hypothesized factor structure identified by Glasgow and colleagues [15]. Given the large modification index, we added one correlation of error covariance. Among the four indices for model fit, our data fit well for the CFI, the TLI, and the RMSEA, but not for the NFI (Table 3).

**Convergent validity.** The K-PACIC-CS correlated significantly and positively with both the CSSES-K ($r = .25, p < .001$) and SF-36 ($r = .25, p < .001$).

**Reliability**

**Internal consistency.** Cronbach’s alpha of the K-PACIC-CS was.94 for the total scale; the results for the subscales are as follows: Patient Activation, .80; Delivery System Design/Decision Support, .76; Goal Setting/Tailoring, .84; Problem Solving/Contextual, .84; and Follow-up/Coordination, .86.

**Discussion**

The PACIC provides a brief patient assessment of the extent to which chronically ill patients report receiving care that is consistent with the CCM [15]. As we consider the application of CCM to Korean cancer survivors, a psychometric evaluation of the K-PACIC-CS is timely and appropriate. Our analyses demonstrated a good fit of the proposed PACIC factorial structure, reasonable convergent validity, and excellent reliability. To the best of our knowledge, this is the first validation study of PACIC for a cancer population, and our findings may contribute to the implementation of CCM-based cancer survivorship care.
### Table 1. Participant characteristics and the K-PAC-CS scores.

| Characteristics                  | n (%) | Mean (SD) | t or F  | p   |
|----------------------------------|-------|-----------|---------|-----|
| **Age (years)**                  |       |           |         |     |
| < 50                             | 70 (34.3) | 3.29 (0.94) | 1.55 | .216 |
| 50–64                            | 96 (47.1) | 3.07 (0.86) |       |     |
| ≥ 65                             | 38 (18.6) | 3.04 (0.88) |       |     |
| **Gender**                       |       |           |         |     |
| Men                              | 25 (12.3) | 3.60 (0.95) | 2.79 | .006 |
| Women                            | 179 (87.7) | 3.08 (0.87) |       |     |
| **Marital status**               |       |           |         |     |
| Married                          | 151 (74.0) | 3.13 (0.92) | -1.13 | .891 |
| Widowed/divorced/single          | 53 (26.0) | 3.15 (0.83) |       |     |
| **Education level**              |       |           |         |     |
| < High school graduation        | 53 (26.0) | 2.99 (0.78) | -1.43 | .154 |
| ≥ High school graduation        | 151 (74.0) | 3.19 (0.93) |       |     |
| **Employment status**            |       |           |         |     |
| Employed                         | 71 (34.8) | 3.27 (0.94) | 1.50 | .455 |
| Unemployed                       | 133 (65.2) | 3.07 (0.86) |       |     |
| **ECOG PS**                      |       |           |         |     |
| 0                                | 123 (60.3) | 3.24 (0.93) | 1.92 | .148 |
| 1                                | 52 (25.5) | 2.99 (0.81) |       |     |
| 2–3                              | 29 (14.2) | 2.98 (0.86) |       |     |
| **Number of cancers**            |       |           |         |     |
| 1                                | 181 | 3.17 (0.90) | 1.42 | .157 |
| 2 or more                        | 22 | 2.88 (0.80) |       |     |
| **Cancer type** (n = 181)        |       |           |         |     |
| Breast                           | 136 (75.1) | 3.15 (0.84) | 3.34 | .021 |
| Thyroid                          | 17 (9.4) | 2.78 (1.17) |       |     |
| Gastrointestinal                 | 19 (10.5) | 3.32 (0.93) |       |     |
| Other\(^a\)                      | 9 (5.0) | 3.90 (0.90) |       |     |
| **Cancer stage**                 |       |           |         |     |
| 0 & 1                            | 42 (20.6) | 2.90 (0.90) | 3.25 | .041 |
| 2                                | 69 (33.6) | 3.09 (0.81) |       |     |
| 3                                | 74 (36.3) | 3.32 (0.93) |       |     |
| **Treatment experience**         |       |           |         |     |
| Surgery                          |       |           |         |     |
| Yes                              | 197 (96.6) | 3.10 (0.88) | 3.28 | .001 |
| No                               | 7 (3.40) | 4.20 (0.66) |       |     |
| Radiation therapy                |       |           |         |     |
| Yes                              | 136 (66.7) | 3.12 (0.86) | 0.33 | .742 |
| No                               | 68 (33.3) | 3.17 (0.96) |       |     |
| Chemotherapy                     |       |           |         |     |
| Yes                              | 143 (70.1) | 3.19 (0.89) | -1.33 | .185 |
| No                               | 61 (29.9) | 3.01 (0.90) |       |     |
| **Months since completion of treatment** |       |           |         |     |
| < 12                             | 64 (31.5) | 3.39 (0.89) | 6.48 | .002 |
| 12–35                            | 58 (28.6) | 3.23 (0.82) |       |     |
| ≥ 36                             | 81 (39.9) | 2.88 (0.89) |       |     |

\(^a\)Participants with a single cancer.

\(^b\)Other includes hematological, gynecological, and prostate cancer.

ECOG PS = Eastern Cooperative Oncology Group performance status; K-PAC-CS = Korean version of the Patient Assessment of Chronic Illness Care for cancer survivors.

https://doi.org/10.1371/journal.pone.0256119.t001
The mean scores on the K-PACIC-CS in our sample were somewhat higher than those reported in non-cancer populations in the US [15] and Europe [21,22,24,45] because of the high mean scores of the Patient Activation (mean = 3.82) and Delivery System Design/Decision Support (mean = 3.74) subscales, which may be explained by the nature of the oncology treatment environment. A multidisciplinary team (MDT) approach with team decision-making is currently the standard of cancer treatment [45], so cancer patients seem to participate more frequently in treatment decisions compared to other chronic patient populations.

Regarding floor and ceiling effects, the results vary greatly. Although the PACIC suffers overall from floor effects versus ceiling effects [14,21,24,25,45,46], that was not evident in our study. We found similar results for floor effects (range, 3.9%– 43.6%; > 30% for five items) and ceiling effects (range, 6.9%– 41.2%; > 30% for five items). Consistent with previous findings [14,21,45–47], we found a floor effect in the Follow-up/Coordination subscale. In particular, Item 17 ("Encouraged to attend program in the community that could help me") had a higher frequency in the lowest response category in several studies (30.7%– 92.5%) [14,21,45–47], including ours (40.7%). This suggests that the current cancer care delivery systems in the acute and primary care settings are not well-coordinated.

### Table 2. Descriptive statistics of the K-PACIC-CS (N = 204).

| Item                          | Mean (SD) | Floor Effect n (%) | Ceiling Effect n (%) |
|-------------------------------|-----------|--------------------|----------------------|
| **Patient Activation**       | 3.82 (1.04) | 3 (1.5)            | 43 (21.1)            |
| Q1                            | 3.97 (1.15) | 8 (3.9)            | 84 (41.2)            |
| Q2                            | 3.76 (1.20) | 10 (4.9)           | 65 (31.9)            |
| Q3                            | 3.75 (1.33) | 19 (9.3)           | 76 (37.3)            |
| **Delivery System Design/Decision Support** | 3.74 (0.97) | 0 (0.0)            | 31 (15.2)            |
| Q4                            | 3.25 (1.37) | 30 (14.7)          | 41 (20.1)            |
| Q5                            | 4.07 (1.02) | 7 (3.4)            | 81 (39.7)            |
| Q6                            | 3.91 (1.11) | 11 (5.4)           | 68 (33.3)            |
| **Goal Setting/Tailoring**    | 3.03 (1.08) | 8 (3.9)            | 7 (3.4)              |
| Q7                            | 3.31 (1.35) | 29 (14.2)          | 45 (22.1)            |
| Q8                            | 3.49 (1.23) | 18 (8.8)           | 47 (23.0)            |
| Q9                            | 2.65 (1.49) | 64 (31.4)          | 34 (16.7)            |
| Q10                           | 3.01 (1.43) | 44 (21.6)          | 35 (17.2)            |
| Q11                           | 2.68 (1.40) | 59 (28.9)          | 23 (11.3)            |
| **Problem Solving/Contextual**| 3.29 (1.07) | 8 (3.9)            | 15 (7.4)             |
| Q12                           | 3.37 (1.32) | 28 (13.7)          | 43 (21.1)            |
| Q13                           | 3.40 (1.28) | 25 (12.3)          | 39 (19.1)            |
| Q14                           | 3.43 (1.22) | 19 (9.3)           | 36 (17.6)            |
| Q15                           | 2.95 (1.37) | 42 (20.6)          | 29 (14.2)            |
| **Follow-up/Coordination**    | 2.36 (1.10) | 34 (16.7)          | 3 (1.5)              |
| Q16                           | 2.59 (1.40) | 55 (27.0)          | 30 (14.7)            |
| Q17                           | 2.24 (1.31) | 83 (40.7)          | 14 (6.9)             |
| Q18                           | 2.26 (1.39) | 86 (42.2)          | 20 (9.8)             |
| Q19                           | 2.49 (1.46) | 79 (38.7)          | 23 (11.3)            |
| Q20                           | 2.23 (1.34) | 89 (43.6)          | 16 (7.8)             |
| **K-PACIC-CS total**          | 3.14 (0.89) |                   |                      |

K-PACIC-CS = Korean version of the Patient Assessment of Chronic Illness Care for cancer survivors.

https://doi.org/10.1371/journal.pone.0256119.t002
We also observed notable floor effects (38.7%–43.6%) in other items (referral to dietician, consultation, and communication related to consultation), which we did not expect because Korea has adopted the MDT approach [48], which involves consultations and referrals. Current MDT practice, however, may be focused on the initial treatment phase, not the survivorship period. According to Maeng and colleagues [48], the MDT focus in Korea is decision-making for further treatment planning and prediction of prognosis. Therefore, we should be careful about interpreting a high floor effect in the Follow-up/Coordination subscale when administering the K-PACIC-CS to long-term cancer survivors.

In addition, Item 9 ("Given a copy of my treatment plan.") showed a high floor effect (31.4%). This contrast with the US value may be related to differences in the US and Korean healthcare systems. In Korea, as opposed to the US, the treatment plan developed by the physician is not shared with the patient, who is not even given a copy of it. Instead, patients are given materials that include information about the next visit and test schedules. Many of our participant responses to Item 9 might have related to those materials rather than the treatment plan. In order to clarify the meaning of Item 9, we recommend using the term ‘자료’ (material) instead of ‘사본’ (copy) when it is translated into Korean.

The CFA analysis showed a good fit with three K-PACIC-CS indices, which supports the five-factor structure predetermined by Glasgow and colleagues [15], and is consistent with the Danish [14] and Dutch studies [23]. Three CFA analyses [18,45,49], however, failed to verify the predetermined five-factor PACIC structure. Other research using the EFA analysis identified a three-factor [24,25] or two-factor structure [24,46,47] (even Gugiu and colleagues [18] suggested the PACIC could be a unidimensional tool). These differences may reflect methodological differences, such as the CFA versus the EFA, study sample differences (e.g., patients with diabetes [24], cardiovascular disease [23], osteoarthritis [19], chronic obstructive respiratory disease [21], or a mixed group [20]), or health system differences (e.g., in the US [15], the UK [45], France [46], the Netherlands [21], Denmark [14], Finland [24], Slovenia [47], and Malaysia [25]).

The K-PACIC-CS had a significant relationship with the CSSES-K and the SF-36 as hypothesized, confirming convergent validity. The correlation coefficient (.25 for each) however, was relatively weak compared to earlier studies [15,47]. Generally, r≥.4 is regarded as optimal [50]. Previous researchers have used the Patient Self-Activation Scale [15] and the EUROPEP instrument to assess patient satisfaction with medical care in the primary care setting [47]. Compared to those tools, self-efficacy for self-management and the HRQOL seem to be more comprehensive. This is a limitation of secondary analysis studies; therefore, further investigation is required.

We provided data of factors associated with the K-PACIC-CS, which could verify known groups validity. Due to lack of prior evidence, we could not determine known groups. We suggest cancer stage (early vs advanced) and time since completion of treatment (short-term survivorship phase vs long-term) as a known group. In the current study, survivors with advanced stage cancer showed higher K-PACIC-CS scores than those in early stages. It is possible that

Table 3. Model fit of confirmatory factor analysis of the K-PACIC-CS (N = 204).

| Fit Index      | χ²   | Df  | p   | CFI | NFI | TLI | RMSEA |
|---------------|------|-----|-----|-----|-----|-----|-------|
| K-PACIC-CS    | 336.24 | 159 | < .001 | .93 | .87 | .91 | .07   |
| Criterion for Good Fit | ≥ 90 | ≥ 90 | ≥ 90 | < .08 |

K-PACIC-CS = Korean version of the Patient Assessment of Chronic Illness Care for cancer survivors.

https://doi.org/10.1371/journal.pone.0256119.t003
patients with advanced cancer are more likely to be involved in decision-making, problem-solving, goal-setting and adjustment, and follow-up. Regarding time since completion of treatment, survivors in the short-term survivorship phase have more frequent visits scheduled than those in long-term survivorship phase, yielding higher K-PACIC-CS scores.

Study limitations
First, our sample consisted mostly of women treated for breast cancer, restricting the generalizability of our findings. Stratified sampling would have been the best choice for this study. Future research using the K-PACIC-CS should report psychometric properties such as Cronbach’s alpha. Second, as this was a secondary analysis study, we tested internal consistency with Cronbach’s alpha only in terms of reliability; there is a need to also examine reproducibility as such test-retest reliability. Third, we did not evaluate responsiveness, which could contribute to a more psychometrically sound tool for testing the effects of a CCM-based intervention. Lastly, the low missing-data rate of this study (0.5%) suggests the possibility that research assistants might have helped participants respond if they faced difficulties understanding items (a limitation following from secondary analysis).

Conclusions
The psychometric properties of the K-PACIC-CS among cancer survivors are satisfactory and suggest a promising way to evaluate cancer survivors’ perspective of a CCM-based survivorship care.

Author Contributions
Conceptualization: Soo Hyun Kim.
Data curation: Yu Hyeon Choe.
Formal analysis: Bo Gyeong Lee.
Funding acquisition: Soo Hyun Kim.
Methodology: Bo Gyeong Lee, Yu Hyeon Choe.
Supervision: Soo Hyun Kim.
Validation: Soo Hyun Kim, Bo Gyeong Lee.
Writing – original draft: Soo Hyun Kim, Bo Gyeong Lee.
Writing – review & editing: Yu Hyeon Choe.

References
1. Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019; 69:363–385. https://doi.org/10.3322/caac.21565
PMID: 31184787
2. Hong S, Won YJ, Park YJ, Park KW, Hong HJ, Lee ES. Cancer statistics in Korea: Incidence, mortality, survival, and prevalence in 2017. Cancer Res Treat. 2020; 52:335–350. PMID: 32178489
3. Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018; 391:1023–1075. https://doi.org/10.1016/S0140-6736(17)33326-3 PMID: 29395269
4. Kline RM, Arora NK, Bradley CJ, Brauer ER, Graves DL, Lunsford NB, et al. Long-term survivorship care after cancer treatment—summary of a 2017 national cancer policy forum workshop. JNCI J Natl Cancer Inst. 2018; 110:1300–1310. https://doi.org/10.1093/jnci/djy176 PMID: 30496448
5. Howell D, Harth T, Brown J, Bennett C, Boyko S. Self-management education interventions for patients with cancer: a systematic review. Support Care Cancer. 2017; 25:1323–1355. https://doi.org/10.1007/s00520-016-3500-z PMID: 28058570

6. Foster C, Breckons M, Cotterell P, Barbosa D, Calman L, Corner J, et al. Cancer survivors’ self-efficacy to self-manage in the year following primary treatment. J Cancer Surviv. 2015; 9:11–19.

7. McCorkle R, Ercolano E, Lazenny B, Schulman-Green D, Schilling LS, Lorig K, et al. Self-management: enabling and empowering patients living with cancer as a chronic illness. CA Cancer J Clin. 2011; 61:50–62. https://doi.org/10.3322/caac.20093 PMID: 21205833

8. Wagner EH, Austin BT, Davis C, Hindmarsh M, Schaefer J, Bonomi A. Improving chronic illness care: translating evidence into action. Health Aff. 2001; 20:64–78. https://doi.org/10.1377/hlthaff.20.6.64 PMID: 11816692

9. Coleman K, Austin BT, Brach C, Wagner EH. Evidence on the Chronic Care Model in the new millennium. Health Aff. 2009; 28:75–85. https://doi.org/10.1377/hlthaff.28.1.75 PMID: 19124857

10. Bodenheimer T. Interventions to improve chronic illness care: evaluating their effectiveness. Disease Management. Mary Ann Liebert Inc.; 2003. pp. 63–71. https://doi.org/10.1089/109350703321908441 PMID: 14577900

11. Tsai AC, Morton SC, Mangione CM, Keeler EB. A meta-analysis of interventions to improve care for chronic illnesses. Am J Manag Care. 2005; 11:478–488. PMID: 16095434

12. Vargas RB, Mangione CM, Asch S, Keeseey J, Rosen M, Schonlau M, et al. Can a chronic care model collaborative reduce heart disease risk in patients with diabetes? J Gen Intern Med. 2007; 22:215–222. https://doi.org/10.1007/s11606-006-0072-5 PMID: 17356989

13. Wagner E. Chronic disease management: what will it take to improve care for chronic illness? Eff Clin Pract. 1998; 1:2–4. https://access.portico.org/Portico/auView?uuid:ark%3A%2F27927%2Fphwtrq3nv PMID: 10345255

14. Maindal HT, Sokolowski I, Vedsted P. Adaptation, data quality and confirmatory factor analysis of the Danish version of the PACIC questionnaire. Eur J Public Health. 2012; 22:31–36. https://doi.org/10.1093/eurpub/ckq188 PMID: 2134901

15. Glasgow RE, Wagner EH, Schaefer J, Mahoney LD, Reid RJ, Greene SM. Development and validation of the Patient Assessment of Chronic Illness Care (PACIC). Med Care. 2005; 43:436–444. https://doi.org/10.1097/01.mlr.0000160375.47920.8c PMID: 15838407

16. Glasgow RE, Whitesides H, Nelson CC, King DK. Use of the Patient Assessment of Chronic Illness Care (PACIC) with diabetic patients: relationship to patient characteristics, receipt of care, and self-management. Diabetes Care. 2005; 28:2655–2661. https://doi.org/10.2337/diacare.28.11.2655 PMID: 16249535

17. Rosemann T, Laux G, Szecsenyi J, Grol R. The Chronic Care Model: congruency and predictors among primary care patients with osteoarthritis. Qual Saf Heal Care. 2008; 17:442–446. https://doi.org/10.1136/qshc.2007.022822 PMID: 19064660

18. Gugiu C, Coryn CLS, Applegate B. Structure and measurement properties of the Patient Assessment of Chronic Illness Care instrument. J Eval Clin Pract. 2010; 16:509–516. https://doi.org/10.1111/j.1365-2753.2009.01151.x PMID: 20210824

19. Rosemann T, Laux G, Droesemeyer S, Gensichen J, Szecsenyi J. Evaluation of a culturally adapted German version of the Patient Assessment of Chronic Illness Care (PACIC 5A) questionnaire in a sample of osteoarthritis patients. J Eval Clin Pract. 2007; 13:806–813. https://doi.org/10.1111/j.1365-2753.2007.00786.x PMID: 17824876

20. Schmittdietl J, Mosen DM, Glasgow RE, Hibbard J, Remmers C, Bellows J. Patient Assessment of Chronic Illness Care (PACIC) and improved patient-centered outcomes for chronic conditions. J Gen Intern Med. 2008; 23:77–80. https://doi.org/10.1007/s11606-007-0452-5 PMID: 18030539

21. Wensing M, Van Lieshout J, Jung HP, Hermens J, Rosemann T. The Patients Assessment Chronic Illness Care (PACIC) questionnaire in the Netherlands: a validation study in rural general practice. BMC Health Serv Res. 2008; 8:182. https://doi.org/10.1186/1472-6963-8-182 PMID: 18761749

22. Aragones A, Schaefer EW, Stevens D, Gourevitch MN, Glasgow RE, Shah NR. Validation of the Spanish translation of the Patient Assessment of Chronic Illness Care (PACIC) survey. Prev Chronic Dis. 2008; 5. PMID: 18793501

23. Cramm JM, Nieboer AP. Factorial validation of the Patient Assessment of Chronic Illness Care (PACIC) and PACIC Short version (PACIC-S) among cardiovascular disease patients in the Netherlands. Health Qual Life Outcomes. 2012; 10:1–7.

24. Simonsen N, Koponen AM, Suominen S. Patients' assessment of chronic illness care: a validation study among patients with type 2 diabetes in Finland. BMC Health Serv Res. 2018; 18:1–10.
25. Abdul-Razak S, Ramli AS, Badlishah-Sham SF, Haniff J, for the EMPOWER-PAR Investigators. Validity and reliability of the Patient Assessment on Chronic Illness Care (PACIC) questionnaire: the Malay version. BMC Fam Pract. 2018; 19:1–11.

26. Lee BG, Lee TS, Kim SH. Mediation effect of self-efficacy on the relationship between perceived self-management support and health-related quality of life among cancer survivors. J Korean Acad Nurs. 2019; 49: 298–306. https://doi.org/10.4040/jkan.2019.49.3.298 PMID: 31266926

27. Kong JX, Zhu L, Wang HM, Li Y, Guo AY, Gao C, et al. Effectiveness of the chronic care model in type 2 diabetes management in a community health service center in China: a group randomized experimental study. J Diabetes Res. 2019; 2019. https://doi.org/10.1155/2019/6516581 PMID: 30719455

28. Schmittied J, Mosen DM, Glasgow RE, Hibbard J, Remmers C, Bellows J. Patient Assessment of Chronic Illness Care (PACIC) and improved patient-centered outcomes for chronic conditions. J Gen Intern Med. 2008; 23:77–80. https://doi.org/10.1007/s11606-007-0452-5 PMID: 18030539

29. Schag CAC, Ganz PA, Heinrich RL. Cancer rehabilitation evaluation system–short form (CARES-SF). A cancer specific rehabilitation and quality of life instrument. Cancer. 1991; 68:1406–1413.

30. Shim EJ, Lee KS, Park JH, Park JH. Comprehensive needs assessment tool in cancer (CNAT): the development and validation. Support Care Cancer. 2011; 19:1957–1968. https://doi.org/10.1007/s00520-010-1037-0 PMID: 21076926

31. Tamburini M, Gangeri L, Brunelli C, Beltrami E, Boeri P, Borreani C, et al. Assessment of hospitalised cancer hospitalised cancer patient’s needs by the needs evaluation questionnaire. Ann Oncol. 2000; 11:31–37. https://doi.org/10.1016/a.1008396930832 PMID: 10690384

32. Chiesi F., Bonacchi A., Primi C., & Miccinesi G. (2017). Assessing unmet needs in patients with cancer: An investigation of differential item functioning of the Needs Evaluation Questionnaire across gender, age and phase of the disease. PloS One, 12(7). https://doi.org/10.1371/journal.pone.0179765 PMID: 28742867

33. Boyes A, Girgis A, Lecathelinais C. Brief assessment of adult cancer patients’ perceived needs: development and validation of the 34-item supportive care needs survey (SCNS-SF34). J E Clin Pract. 2009; 15:602–606. https://doi.org/10.1111/j.1365-2753.2008.01057.x PMID: 19522727

34. Kim YE. The development of a Patient Assessment of Chronic Illness Care (K-PACIC). Korea University, South Korea. 2015.

35. Kim SH, Lee BG, Lee JY, Kim SJ, Hur MH, Lee MH, et al. Psychometric evaluation of a Korean version of the Cancer Survivors’ Self-Efficacy Scale. Cancer Nurs. 2019; 42:509–514. https://doi.org/10.1097/NCC.0000000000000691 PMID: 30601268

36. Coates C. The evaluation of measuring caring: moving toward construct validity. second. In: Watson J, editor. Assessing and measuring caring in nursing and health science. second. New York: Springer Publishing; 2009.

37. VanderZee KI, Sanderman R, Heyink JW, De Haes H. Psychometric qualities of the RAND 36-item health survey 1.0: a multidimensional measure of general health status. Int J Behav Med. 1996; 3:104–122. https://doi.org/10.1207/s15327558ijbm0302_2 PMID: 16250758

38. RAND Corporation. 36-item short form survey from the RAND Medical Outcomes Study (MOS). 1997 [cited 5 Jul 2020]. http://www.rand.org/health/surveys_tools/mos/mos_core_36item.html.

39. Everett B, Salamondon Y, Davidson PM. Bandura’s exercise self-efficacy scale: validation in an Australian cardiac rehabilitation setting. Int J Nurs Stud. 2009; 46:824–829. https://doi.org/10.1016/j.ijnurstu.2009.01.016 PMID: 19261281

40. Cronk B. How to use SPSS: a step by step guide to analysis and interpretation. third. Glendale, CA: Pyrzcak Publishing; 2004.

41. Steiger JH. Understanding the limitations of global fit assessment in structural equation modeling. Pers Individ Dif. 2007; 42:893–898. https://doi.org/10.1016/j.paid.2006.09.017

42. Aung E, Ostini R, Dower J, Donald M, Coll JR, Williams GM, et al. Patient Assessment of Chronic Illness Care (PACIC) in Type 2 Diabetes: a Longitudinal Study. Eval Heal Prof. 2016; 39:185–203. https://doi.org/10.1177/0163278714556674 PMID: 25380699

43. Kim SH, Kim K, Mayer DK. Self-management intervention for adult cancer survivors after treatment: a systematic review and meta-Analysis. Oncology Nursing Forum. Oncology Nursing Society; 2017. pp. 719–728. https://doi.org/10.1188/17.ONF.719-728 PMID: 29052663

44. Nunnally JBI. Psychometric theory. third. New York: McGraw-Hill; 1994.

45. Rick J, Rowe K, Hann M, Sibbald B, Reeves D, Roland M, et al. Psychometric properties of the patient assessment of chronic illness care measure: acceptability, reliability and validity in United Kingdom patients with long-term conditions. BMC Health Serv Res. 2012; 12:1–15.

46. Krucien N, Le Vaillant M, Pelletier-Fleury N. Adaptation and validation of the patient assessment of chronic illness care in the French context. BMC Health Serv Res. 2014; 14:1–12.
47. Tušek-Bunc K, Petek-Šter M, Šter B, Petek D, Kersnik J. Validation of the Slovenian version of Patient Assessment of Chronic Illness Care (PACIC) in patients with coronary heart disease. Coll Antropol. 2014; 38:437–444. PMID: 25144971

48. Maeng CH, Ahn HK, Oh SY, Lim S, Kim BS, Kim DY. Practice patterns of multidisciplinary team meetings in Korean cancer care and patient satisfaction with this approach. Korean J Intern Med. 2020; 35:205–214. PMID: 31795023

49. McIntosh C. Examining the factorial validity of selected modules for the Canadian survey of experiences with primary health care. Ottawa: Health Research Working Paper Series; 2008.

50. McDowell I, Newell C. Measuring health: a guide to rating scales and questionnaires. second. New York: Oxford University Press; 1996.